Presentation on theme: "Advancements In Anticoagulation John Devlin, Pharm D Feb 4, 2009."— Presentation transcript:
Advancements In Anticoagulation John Devlin, Pharm D Feb 4, 2009
Agenda 1.Unmet needs in anticoagulation 2.Niche for new anticoagulants 3.Dabigatran Etexilate 4.Evidence for efficacy and safety from phase 3 randomized trials 5.Implications for clinical practice 6.Comparing agents 7.Future developments
Place in therapy Venous thrombosis Prevention –In-hospital –Out-of-hospital Treatment – Initial – Long term Arterial thrombosis Treatment – ACS Prevention – Stroke (AF, CHF, Prosthetic valves) – Post MI – PCI / HD
The “Magic Bullet” Oral Dosage Form Little or no monitoring required Equally efficacious and safe to current treatments Consistent dosing regimen (wide therapeutic window) Predictable PK and PD Free from alcohol and food interactions Free from drug interactions Un phased by genetic factors (VKOR, CYP2C9) Un phased by organ dysfunction Reversibility Rapid onset and offset Inexpensive
Urgent Need to Replace Warfarin!
Where Can We Improve? Venous thrombosis Prevention –In-hospital –Out-of-hospital Treatment – Initial – Long term Arterial thrombosis Treatment – ACS Prevention – Stroke (AF, CHF, Prothestic heart valves) – Post MI – PCI / HD
VTE Prevention “Call to Action” on DVT and PE September 15, 2008 (Washington, DC) - The Office of the Surgeon General called today for a coordinated, multifaceted plan to reduce the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the us. The “call to action” is intended to increase awareness about these silent conditions and emphasize the importance of evidence based practices in the management of DVT.
Out of Hospital Underuse of Extended Prophylaxis after major Orthopedic Surgery ACCP guidelines for extended prophylaxis: Hip fracture 1A Hip arthroplasty 1A Knee arthroplasty 2B Reasons for underuse Need for subcut injection Need for monitoring and dose adjustment of VKA therapy Coordinating drug coverage
VTE Prevention Non Traditional Prophylaxis Medical patients (EXCLAIM trial) 4000 patients 6-14 days vs 1 month with LMWH > 14 days? Knee arthroscopy (KANT trial) 1800 patients Nadroparin 3800 units vs elastic stockings for 7 days 0.9% vs 3.2 % Thalidomide associated VTE
Long Term Secondary VTE Prophylaxis Duration of anticoagulation for first unprovoked VTE Proximal DVT or PE, no bleeding risk factors, and good monitoring is available Those with permanent risk factors (ie Cancer) Unprovoked VTE with strong preference for less frequent monitoring.
New Oral Anticoagulant Targets Common Pathway IX X VIII Xa Thrombin Fibrin Thrombin Activity Initiation Phase Amplification Propagation Phase Platelet Surface XII XI Contact Fibrinogen Rivaroxaban Apixaban Dabigatran Etexilate TF/VII
Anti-Xa or Anti-IIa? Pharmacologic Considerations Anti-XaAnti-IIa “Gatekeeper of the coagulation cascade” “Final Common Pathway” Block thrombin generationBlock thrombin activity Selective “targeted” effectBlock Contact Activation Maintain -ve feedbackBlock +ve feedback Platelet Inhibition
Key Characteristics Indicated for prevention of VTE post THR & TKR Dose 110 mg 1-4 hours post surgery followed by 220 mg daily
Dabigatran Pharmacokinetics Absorption Oral Bioavailability: ~ 6.5% Time to peak: hours, delayed 2 hours by food Distribution Linear kinetics ~35% protein bound Vd = 60-70L
Dabigatran Pharmacokinetics Metabolism Hepatic glucuronidation to active metabolite Elimination Excreted in urine (85%, primarily as unchanged drug); fecal (6% of total dose) t 1/2 = hours
Drug Interactions Avoid concomitant use with p-glycoprotein inhibitors & inducers Verapamil, Clarithromycin, *Quinidine Rifampicin, St. Jonh’s Wort, Tenofovir) Antacids diminished clinical effect; avoid within 24 hours after surgery Amiodarone Adjust dosing to 150 mg daily dabigatran with amiodarone Pantoprazole Co-administration with Dabigatran may diminish clinical effect
Special Considerations Contraindications Severe renal impairment (CrCl < 30 mL/min) Concomitant treatment with strong P-Glycoprotein inhibitors (Quinidine) Antidote Switching agents Special Patient Populations Age Pregnancy Weight End organ dysfunction
Dabigatran Phase III Studies: REVOLUTION Start evening before surgery* OR hours post-operatively # Start 1-4 hours* OR 6-12 hours # post-operatively Enoxaparin 40 mg QD* OR 30 mg BID # Dabigatran etexilate 75 / 150 mg QD Venography Within 12 hours of last dose Follow-up 12–14 weeks Eriksson et al. J Thromb Haemost 2007; Eriksson et al. Lancet 2007; Ginsberg et al. J Arthroplast. DOI: /j.arth *RE-MODEL and RE-NOVATE # RE-MOBILIZE Design:Non-Inferiority in Modified Intention-To-Treat Population R R Dabigatran etexilate 110 / 220 mg QD Study Therapy Duration Enoxaparin Dose (mg) RE-MODELKnee6-10 days40 QD RE-NOVATEHip28-35 days40 QD RE-MOBILIZEKnee12-15 days30 BID
Methods - Procedures Primary efficacy outcome: Composite of total venous thromboembolic events (VTE) (symptomatic or venographic DVT and/or pulmonary embolism [PE]), and all-cause mortality during treatment Secondary efficacy outcomes: Composite of major VTE (proximal DVT and PE) and VTE-related mortality Proximal DVT Incidence of total VTE and all-cause mortality during follow-up Individual components of the primary outcome TrialCountries# SitesSample Size RE-MODEL Europe, Australia, South Africa RE-NOVATE RE-MOBILIZE US, Canada, Mexico, UK Eriksson et al. J Thromb Haemost 2007; Eriksson et al. Lancet 2007; Ginsberg et al. J Arthroplast. DOI: /j.arth
Methods - Procedures Primary safety outcome: – Major bleeding events – Associated with ≥2 g/dL drop in haemoglobin or required transfusion of ≥2 units blood – Fatal, retroperitoneal, intracranial, intraocular, or intraspinal – Warranted treatment cessation or re-operation – Clinically relevant non-major bleeding events – Minor bleeding events Events were classified by an independent, expert adjudication committee Eriksson et al. J Thromb Haemost 2007; Eriksson et al. Lancet 2007; Ginsberg et al. J Arthroplast. DOI: /j.arth
Baseline characteristics RE-MOBILIZERE-MODELRE-NOVATE Patient Characteristics Age (mean) - years Females - % Weight (mean) – kg Anesthetic Details General - % Study Drug Administration Time to first oral dose* (mean) – h Treatment duration (median) – d 13833
P= for non-inferiority RE-MODELRE-MOBILIZE † RE-NOVATE P=0.017 for non-inferiority P< for non-inferiority Primary Efficacy Outcome: Total VTE or All-Cause Mortality (Hip) (Knee) Dabigatran Enoxaparin Eriksson et al. J Thromb Haemost 2007; Ginsberg et al. J Arthroplast. DOI: /j.arth ; Eriksson et al. Lancet 2007 P=0.02 * * P-value that the margin of 9.2% as the upper limit of the 95% CI for ARD was exceeded P= * † Confidence intervals not reported
RE-MODELRE-MOBILIZE*RE-NOVATE No significant differences between either dose of dabigatran etexilate and enoxaparin. Safety Outcome: Major Bleeding Events * Confidence intervals not reported Dabigatran Enoxaparin Eriksson et al. J Thromb Haemost 2007; Ginsberg et al. J Arthroplast. DOI: /j.arth ; Eriksson et al. Lancet 2007
Interpretational Considerations Failure to demonstrate non-inferiority of dabigatran in Re-Mobilize Factors that may have contributed Higher dose of enoxaparin (30 mg BID vs 40 mg QD in RE-MODEL) Comparator event rate was lower than anticipated (25.3% versus 37.7% in RE-MODEL) Different median duration of treatment Delayed initiation of dabigatran dosing
Efficacy by Timing of Initiation of Dabigatran (70/498)(121/539) Total VTE Rate (%) P = Eriksson et al. J Thromb Haemost 2005 A post-hoc analysis from BISTRO II (THR & TKR patients)
Meta-Analysis of RE-MODEL, RE-MOBILIZE, RE-NOVATE: Total VTE & All-Cause Mortality Wolowacz et al. Thromb Haemost Favours Enoxaparin Favours Dabigatran Etexilate RE-MOBILIZE188/604163/643 RE-MODEL183/503193/512 RE-NOVATE 53/880 60/897 Study or sub- category Dabigatran etexilate 220 mg QD n/N Enoxaparin n/N RR [95% CI] 1.23 [1.03, 1.47] 0.97 [0.82, 1.13] 0.90 [0.63, 1.29] Total events: 424 (dabigatran etexilate), 416 (enoxaparin) Test for heterogeneity: Chi 2 = 4.73, df = 2 (P=0.09), I 2 = 57.7% Random Effects Analysis Total (95% CI) Test for overall effect: Z = 0.47 (P = 0.64) 1.05 [0.87, 1.26] RR Analysis is based on the 220 mg QD dose of dabigatran etexilate.
The “Magic Bullet”……. Oral Dosage Form Little or no monitoring required Equally efficacious and safe to current treatments Consistent dosing regimen Predictable PK and PD Free from alcohol and food interactions Free from drug interactions Un phased by genetic factors (VKOR, CYP2C9) Un phased by organ dysfunction Reversibility Rapid onset and offset Inexpensive
…..Not entirely yet much better! Oral Dosage Form Little or no monitoring required Equally efficacious and safe to current treatments Consistent dosing regimen Predictable PK and PD Free from alcohol and food interactions Free from drug interactions X Un phased by genetic factors (VKOR, CYP2C9) Un phased by organ dysfunction X Reversibility X Rapid onset and offset Inexpensive
Implications for Clinical Practice Dabigatran etexilate is safe and effective for prevention of VTE in patients undergoing hip or knee arthroplasty Potential to replace LMWH or fondaparinux Major unmet need is out of hospital prophylaxis Potential to improve guideline adherence and reduce VTE disease burden
Summary Massive unmet need for new oral anticoagulant Dabigatran etexilate Simple Convenient, unmonitored Safe Effective First in AF (September 2009) Closing the care gap – more patients treated appropriately with improved quality of life. Excellent replacement for warfarin